Alessandro Aiuti is Deputy Director, Clinical Research Coordinator, Head of Unit on Pathogenesis and Therapy of PID and Head of Pediatric Clinical Research Unit of the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget) in Milan; Director of the Pediatric Immunohematology Unit, San Raffaele Hospital, Milan; full Professor of Pediatrics at the Vita-Salute San Raffaele University in Milan, Italy; Director of the Residency Program of Pediatrics, Vita-Salute San Raffaele University in Milan, Italy.
He is M.D., specialized in Immunology and Ph.D. in Molecular and Cell Biology. In 1998 he obtained the National Board in Hematology.
Since 1994 he has been working at the San Raffaele Telethon Institute for Gene Therapy (HSR-TIGET), Milan, Italy, as Post Doctoral fellow (1994- 1996), Group Leader (1997-2003), Head of Research Unit (2003-present) and, presently, as Deputy Director and Clinical Research Coordinator.
From 2000 to 2007 he worked as M.D. Research Scientist for the Scientific Institute H.S. Raffaele, Milan, Italy, and from 2007 to 2014 as Associate Professor of Pediatrics at the University of Rome Tor Vergata/Bambino Gesù Hospital, Rome, Italy. He received several awards, including Young Investigator Award (ASGCT) and ESGCT award for outstanding career and pioneering contributions to the field. He is author of more than 150 peer reviewed publications (total citations of 8627, h-index Scopus 42). He is board member of the ESGCT since 2012. From 2013 to 05/2016 he was Chair of ASGCT Hematopoietic Cell Gene Therapy Committee, and from 2010 to 2102 he was member of Gene Therapy Working Party of European Medicines Agency (EMA).
His main interests are hematology, immunology and pediatrics, particularly in primary immunodeficiencies and gene therapy for Severe Combined Immunodeficiency due to the lack of Adenosine Deaminase (ADA-SCID) and Wiskott-Aldrich Syndrome. His main domain of research are: Gene transfer into human HSC, gene therapy of PID and other genetic diseases (PI of 4 clinical trials: ADA-SCID, WAS, beta thalassemia and metachromatic leukodystrophy gene therapy), genetic and immunological characterization of PID in children, immune reconstitution after BMT and gene therapy.